TESTS: the large thymosin alpha-1 sepsis trial was negative overall

The TESTS trial did not establish a reduction in 28-day mortality with thymosin alpha-1 in adults with sepsis. It is also important to read its correction: the original abstract still circulates with an older hazard ratio. A reliable summary should identify the corrected result and preserve the overall negative conclusion rather than selecting a favorable subgroup or an outdated estimate.

What the trial tested

TESTS was a double-blind, placebo-controlled phase 3 study across 22 centers in China. It randomized 1,106 adults with sepsis; 1,089 entered the modified intention-to-treat analysis. The intervention was subcutaneous thymosin alpha-1 in a hospital treatment context. This was not a study of healthy people seeking general immune support or prevention of everyday infections.

The corrected estimate

The May 30, 2025 BMJ correction changed the 28-day mortality hazard ratio from 0.99 to 0.97, with a corrected 95% confidence interval of 0.76-1.24. It also changed the 90-day hazard ratio to 0.95 (0.77-1.17), amended lymphocyte data and revised the data-sharing statement. The correction did not establish a significant mortality benefit.

A hazard ratio near one with a confidence interval spanning one does not establish improved survival. It also does not prove the two treatments are exactly equivalent in every possible population. The useful interpretation is narrower: this trial did not provide clear evidence of the proposed mortality benefit under its studied conditions. Uncertainty should be stated in both directions.

Why the main result comes first

A randomized trial identifies a primary question before its results are known. That question should anchor the summary. Other outcomes and subgroup patterns can help researchers investigate explanations or plan another experiment, but they do not erase a negative primary finding. A page beginning with a favorable subgroup while omitting the overall result gives the reader a distorted picture.

Ask whether a subgroup was specified in advance, whether an interaction was tested and whether the analysis accounted for multiple comparisons. Even an interesting subgroup needs confirmation before it becomes a dependable treatment-selection rule. Do not infer that a demographic characteristic alone identifies a group proven to benefit.

Keep clinical relevance separate from biological plausibility

An immunomodulatory mechanism can make a trial worth conducting. It cannot determine the result in advance. Sepsis is a particular clinical syndrome, and survival is a different outcome from a change in immune-cell counts. A plausible explanation for why treatment might work should be evaluated alongside the outcome data rather than used to dismiss them.

A reading checklist for TESTS claims

• Does the summary state that the overall mortality result was negative?
• Does it link the corrected article and the correction notice?
• Does it identify the hospital sepsis population and subcutaneous route?
• Does it distinguish the primary outcome from exploratory findings?
• Does it avoid converting the trial into a routine wellness or longevity claim?

For a clinical discussion, bring the paper and correction together. Ask which proposed indication is being considered and whether any stronger, directly relevant evidence changes the interpretation. TESTS contributes important information precisely because it tested a meaningful patient outcome in a substantial randomized population. Reporting its negative result clearly is part of understanding thymosin alpha-1, not a reason to omit the study.